Biosimilar Coding Policy For Medicare Reversed To 'Promote Innovation'
Decision reflects Trump Administration's willingness to reconsider past efforts at cost control to address biopharma industry's concerns.
You may also be interested in...
Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars under Medicare Part B in comments to the Centers for Medicare and Medicaid Services.
Launch of a second infliximab biosimilar by Merck triggers Medicare's controversial biosimilars reimbursement policy for the first time.
Policy of paying for all biosimilars referencing the same drug at one blended rate is under review, to the relief of product developers and other stakeholders.